SCHEMBL2222912

SCHEMBL2222912

O=C(Br)c1ccccc1CBr

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
TSHR P16473 3/20 0.40
FOLH1 Q04609 1/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 2/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 6/20 0.39
ALOX15 P16050 1/20 0.39
TRPA1 O75762 1/20 0.39
PTPN1 P18031 2/20 0.38
ADRB2 P07550 1/20 0.37
GSK3B P49841 1/20 0.37
AKR1B1 P15121 1/20 0.35
BCAT2 O15382 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3135339 0.84 FOLH1 (0.41) CES2CES1TSHRFOLH1LMNA
SCHEMBL445508 0.82 FOLH1 (0.59) TSHRFOLH1HPGDGAAALDH1A1
SCHEMBL30565103 0.82 FOLH1 (0.59) TSHRFOLH1HPGDGAAALDH1A1
SCHEMBL3173852 0.82 GABRA1 (0.44) TSHRFOLH1LMNAHPGDGAA
Hydrochloric Acid SCHEMBL3312470 0.80 FOLH1 (0.57) TSHRFOLH1HPGDGAAALDH1A1
SCHEMBL8227007 0.80 ALDH1A1 (0.44) TSHRFOLH1LMNAHPGDALDH1A1
SCHEMBL2588305 0.80 KDM4E (0.50) TSHRHPGDGAAL3MBTL1ALDH1A1
SCHEMBL1792164 0.80 ALDH1A1 (0.48) CES2CES1TSHRFOLH1LMNA
SCHEMBL8096274 0.79 GABRA1 (0.48) TSHRLMNAHPGDALDH1A1KMT2A
SCHEMBL491271 0.78 ALDH1A1 (0.47) TSHRFOLH1LMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107376875-A A kind of preparation and application of the beta cyclodextrin porous material with quick adsorption ability 湖南理工学院 2017-11-24 CN claimed
CN-103739786-B Macromolecule quaternary salt anti-biotic material and preparation method thereof 河南金誉包装科技股份有限公司 2016-08-17 CN claimed
CN-103739786-B Macromolecule quaternary salt anti-biotic material and preparation method thereof 河南金誉包装科技股份有限公司 2016-08-17 CN disclosed
WO-2011087758-A1 ADAMANTYL AMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2011-07-21 WO disclosed
US-7803950-B2 Method for the production of diarylcycloalkyl derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-09-28 US disclosed
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-28 US disclosed
US-20070197614-A1 METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
US-7189864-B2 Method of preparing intermediates useful in synthesis of retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-03-13 US disclosed
US-7094795-B2 Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-08-22 US disclosed
US-6974876-B2 Method for preparing intermediates useful in synthesis of retroviral protease inhibitors G.D. SEARLE & CO. (US) 2005-12-13 US disclosed
US-20050171366-A1 Method of preparing intermediates useful in synthesis of retroviral protease inhibitors G.D. SEARLE & CO. (US) 2005-08-04 US disclosed
EP-0625978-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1994-11-30 EP disclosed
WO-1993023388-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1993-11-25 WO disclosed
EP-0563345-A1 NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES MCNEILAB, INC. (US) 1993-10-06 EP disclosed
EP-0562049-A1 NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES MCNEILAB, INC. (US) 1993-09-29 EP disclosed
WO-1993016073-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1993-08-19 WO disclosed
WO-1993004682-A1 NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES MCNEILAB, INC. (US) 1993-03-18 WO disclosed
WO-1993004684-A1 NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES MCNEILAB, INC. (US) 1993-03-18 WO disclosed
US-4289781-A Anti-psychotic phthalimidine derivatives ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1981-09-15 US disclosed
EP-0026749-A1 Phthalimidine derivatives and pharmaceutical compositions containing them Astra Läkemedel Aktiebolag (SE) 1981-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171366-A1 Method of preparing intermediates useful in synthesis of retroviral protease inhibitors PREP, DNPEP, ANPEP CES2 67/4885CES1 94/4885TSHR 4807/4885
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES PPARG, PPARD, PPARA CES2 998/4885CES1 896/4885TSHR 935/4885
US-20070197614-A1 METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES PPARA, PPARD, PPARG CES2 913/4885CES1 574/4885TSHR 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.